Allergan

Allergan plc (NYSE: AGN) is a distinguished global pharmaceutical company, pioneering a unique industry model termed Growth Pharma. Operating within the vital Healthcare and Pharmaceuticals sectors, Allergan is dedicated to the development and delivery of innovative therapeutic treatments. The company's strategic vision centers on this distinctive industry model, engineered to foster sustained growth and secure market leadership through scientific excellence and a robust pipeline.

The operational scale of Allergan is supported by a dedicated workforce ranging from 500 to 1,000 employees. This team drives the company's significant market presence, reflected in its substantial revenue of $433.4M. Allergan's commitment to scientific advancement is paramount, with extensive research and development efforts focused on bringing novel therapeutic agents and treatments to fruition. Meet Allergan's team to gain insight into the collective expertise and leadership guiding these critical initiatives.

Allergan's comprehensive product portfolio encompasses a diverse array of treatments, with notable emphasis on specialized eye preparations and cutting-edge novel therapeutic agents. The company's state-of-the-art R&D centers are the hubs for pioneering science, dedicated to creating best-in-class solutions. This unwavering focus on innovation enables Allergan to effectively address unmet medical needs and significantly enhance patient care through its pipeline of advanced treatments and agents, solidifying its position as a global pharmaceutical leader.